Literature DB >> 29222923

Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.

Emily R Nicholson1, Julian E Dilley1, Janice C Froehlich1.   

Abstract

BACKGROUND: This study examined whether combining naltrexone (NTX) with bupropion (BUP) is more effective in reducing alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high voluntary alcohol intake than either drug alone.
METHODS: Alcohol-experienced, adult, male, P rats were fed NTX alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 20.0 mg/kg BW, NTX (10.0 mg/kg BW) + BUP (10.0 mg/kg BW), or vehicle (VEH) at 1 hour prior to onset of a daily 2-hour alcohol access period for 5 consecutive days.
RESULTS: When administered alone, neither NTX (10.0 mg/kg BW) nor BUP, in either of 2 doses (10.0 mg/kg BW or 20.0 mg/kg BW), reduced voluntary alcohol intake in P rats. However, NTX combined with BUP (10.0 mg/kg NTX + 10.0 mg/kg BUP) and given as a single medication significantly reduced alcohol consumption throughout prolonged treatment.
CONCLUSIONS: Combining low doses of NTX and BUP, each of which is ineffective when given alone, increases the efficacy of the medication. Low drug doses circumvent the problem of negative side effects that can occur with higher doses of either drug. A reduction in side effects can facilitate patient compliance and improve clinical outcomes for alcoholics and heavy drinkers who want to reduce their alcohol intake. The results, together with those from our prior studies, demonstrate the strength of a combinatorial pharmacotherapeutic approach to the treatment of alcohol use disorder.
Copyright © 2017 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Drinking; Alcohol Treatment; Bupropion; Naltrexone; Selectively Bred Rats

Mesh:

Substances:

Year:  2018        PMID: 29222923      PMCID: PMC5832575          DOI: 10.1111/acer.13577

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  51 in total

1.  Overexpression of dopamine D2 receptors reduces alcohol self-administration.

Authors:  P K Thanos; N D Volkow; P Freimuth; H Umegaki; H Ikari; G Roth; D K Ingram; R Hitzemann
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

Review 2.  Trends in the adoption of medications for alcohol dependence.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

3.  Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.

Authors:  Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

4.  Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Authors:  Janice C Froehlich; Brett Hausauer; Stephen Fischer; Bradley Wise; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2015-08       Impact factor: 3.455

5.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

6.  Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.

Authors:  Charles J Heyser; Kelly Moc; George F Koob
Journal:  Neuropsychopharmacology       Date:  2003-04-09       Impact factor: 7.853

7.  Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Authors:  R Scott Obach; Anne E Reed-Hagen; Suzanne S Krueger; Beth J Obach; Thomas N O'Connell; Kathleen S Zandi; Sandra Miller; Jotham W Coe
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

8.  Alcohol and bupropion pharmacokinetics in healthy male volunteers.

Authors:  J Posner; A Bye; S Jeal; A W Peck; P Whiteman
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Authors:  Lara A Ray; Kelly E Courtney; Dara G Ghahremani; Karen Miotto; Arthur Brody; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2014-04-15       Impact factor: 4.530

10.  Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.

Authors:  Christian S Hendershot; Jeffrey D Wardell; Andriy V Samokhvalov; Jürgen Rehm
Journal:  Addict Biol       Date:  2016-07-14       Impact factor: 4.280

View more
  4 in total

1.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

2.  Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice.

Authors:  Montserrat Navarro; Kendall L Luhn; Alexey B Kampov-Polevoy; James C Garbutt; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2019-03-19       Impact factor: 3.455

3.  Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.

Authors:  Yan Zhou; Francesco Leri; Malcolm J Low; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2019-04-13       Impact factor: 3.533

Review 4.  The melanocortin system as a potential target for treating alcohol use disorders: A review of pre-clinical data.

Authors:  José Manuel Lerma-Cabrera; Francisca Carvajal; James C Garbutt; Montserrat Navarro; Todd E Thiele
Journal:  Brain Res       Date:  2019-12-28       Impact factor: 3.252

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.